Daiichi ends hydrocodone deal with Charleston Labs

Daiichi Sankyo Co. Ltd. (Tokyo:4568) terminated a 2014 deal with Charleston Laboratories Inc. (Jupiter, Fla.) to develop and commercialize Charleston's hydrocodone products in the U.S., including lead compound CL-108. The private company regains all rights to the portfolio.

Daiichi said it has decided to refocus its commercial efforts on its current products for the U.S. pain market following a portfolio and market review...